Argonaute RNA Ltd — SEC Form D Filing

Argonaute RNA Ltd filed an SEC Form D on September 24, 2026, reporting $1.80M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 24, 2026
Amount reported
$1.80M
Round stage
Seed
Industry
Biotechnology
Website
https://argonauterna.com/

What the company does

Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: UNITED KINGDOM

Problem

There are life-threatening areas of clinical unmet need in cardiometabolic diseases that require precise, short-duration gene silencing. Additionally, complex multi-factorial diseases are challenging to treat when silencing only a single gene, and developing stable and effective siRNA drugs for human use has faced significant obstacles.

Solution

Argonaute RNA develops bispecific siRNA therapeutics, including PULSE siRNA™ for acute indications requiring rapid recovery and Argo Dual siRNA for complex multi-factorial diseases. These proprietary modified siRNAs are stabilized to safely and effectively silence specific gene expression by inhibiting protein production, overcoming previous development challenges.

Why now

Advances in RNA interference technology and growing demand for precision medicine solutions allow for the development of more stable and effective siRNA therapeutics for previously untreatable or difficult-to-treat diseases.

Verdict

This cleared because investors saw a credible technical approach to a well-understood biological mechanism, not because the specific clinical targets were de-risked. They implicitly bet on the platform's ability to generate multiple novel drug candidates and attract larger pharmaceutical partners through improved stability and specificity. Upside was limited by the long development cycles inherent in drug discovery and the crowded field of RNA therapeutics, suggesting a platform play rather than a quick clinical win.

Source: SEC EDGAR Form D filing